IQVIA™ Pharma Deals: Review and Analysis

IQVIA Pharma Deals Review

ISSN 1756-7874. The business journal providing incisive analysis and expert opinion on the major deals.

Pharma Deals Review Latest Articles

Merck & Co. Expands Haematology Portfolio with US$6.7 B Acquisition of Terns Pharmaceuticals Published: 31 Mar-2026
By: Nikita Negi
Abstract Fulltext:
Volume: 2026 Issue: 3
Merck & Co. Inks US$2.2 B IBD Target Discovery Collaboration with Quotient Therapeutics Published: 31 Mar-2026
By: Hitesh Udar
Abstract Fulltext:
Volume: 2026 Issue: 3
IQVIA Pharma Deals Review of 2025 Published: 27 Mar-2026
By: Lucy Haggerty,Taskin Ahmed, Ayush Saxena & Shikha Kashyap
Abstract Fulltext:
Volume: 2026 Issue: 3
Lilly Pays US$2.4 B to Acquire Orna Therapeutics and its CAR-T Cell Therapies for Autoimmune Diseases Published: 3 Mar-2026
By: Naini Anand
Abstract Fulltext:
Volume: 2026 Issue: 3
Madrigal Pharmaceuticals Strikes Global Licensing Pact with Suzhou Ribo Life Science to Advance siRNA Metabolic Programmes Published: 26 Feb-2026
By: Nikita Negi & Lucy Haggerty
Abstract Fulltext:
Volume: 2026 Issue: 2

You can click on any of the bars to open a new page with the corresponding deals.

Login Problems

Please enter your username or email address and we will email you your login details.

Latest Article

Merck & Co. Expands Haematology Portfolio with US$6.7 B Acquisition of Terns Pharmaceuticals

Published: 31 Mar-2026
By: Nikita Negi Abstract Fulltext:

ANNUAL DEAL REVIEW OF 2025

Click Here to Access the Article

IQVIA™ Pharma Deals: Review and Analysis